The investment objective of the Fund is to track the performance before fees and expenses of an index which is designed to reflect the performance of the shares of large, medium, and small-capitalisation companies that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector and which promote, among other characteristics, environmental and social characteristics.